

metabolytix

The Continuous Metabolic Monitoring Platform



a **CANCER FUND** portfolio company
VENTURE LABS

WHY CANCER FUND IS INVESTING IN METABOLYTIX

CANCER FUND invests in innovations with potential to impact patients, survivors, and at-risk populations



An Immediate Community Need:

~14% of chemotherapy patients experience Acute Kidney Injury (AKI); up to ~50% for certain types of cancer*



Part of Our Management & Prevention Strategy:

High frequency low-cost monitoring and diagnostics



Aligns with Our Impact Goals:

Reduce AKI in chemo patients



A Viable Impact Investment Opportunity:

Fits our investment plan, criteria, and target returns

CANCER FUND supports Metabolytix to reduce AKI Cancer Patients

* Nature 2019

MARKET OPPORTUNITIES IN ONCOLOGY AND COMORBIDITIES

Basic Metabolic Panel (BMP) data is a key component of medical diagnosis and treatment in healthcare

In 2019, Medicare Part B Reimbursed 7,059,894 BMP tests (CPT CODE: 80048)

	Oncology	Cardiology	Renal Care	General Healthcare
Application	Monitoring and diagnosis during therapeutic treatment	Monitoring kidney function during titration of medication	Monitoring renal system performance during diagnosis and treatment	Monitoring and tracking key metabolic measures during hospitalization and treatment
# of Tests Annually	~850,000 tests/ year	~130,000 test/ year	~42,000 tests/ year	~225,000 tests/ year

Today's methods of collecting BMP data enable but don't facilitate treatment Real Time

TODAY'S BASIC METABOLIC PANEL (BMP)

Blood Draws, Lab Processing, and Physician Review Disrupts Patient Lives

1

Painful

Requires
Blood Draw

2

Slow

Requires Lab
Processing

3

Costly

\$120-180
In-Hospital Test
(CPT 80061)

4

Infrequent

Single Time
Point Test

5

Inaccessible

Requires staffed
hospital, labs,
clinics

BMP Measures

Potassium	BUN
Sodium	Creatinine
Chloride	Calcium
Bicarbonates	Glucose

BMP Assesses:

- Fluid balance electrolytes
- Metabolism
- Liver and kidney function
- Acid/base balance
- Blood glucose

Today's BMP negatively impacts patient outcomes

CONTINUOUS BMP (cBMP) COULD IMPROVE OUTCOMES

More Frequent cBMP Offers Convenience to Patients, Improved Data for Providers, Lower Cost for Payers

Patient Benefits

- Convenient Wearable Device
- No Blood Draw - Reduced Lab Visits
- High Test Frequency > Improved Outcomes

Provider Benefits

- Simplified Hospital Operation
- Automated data collection and monitoring with Real Time Results

Payer Benefits

- \$500 Pricing : Targeting 66% less than current methods (Based on 3 tests per day for 3 day hospitalization, 9 tests total)

Broad Applicability

- In-patient
- Outpatient
- At Home Care and Mobile Care

Initial Target Markets

MVP - CRAM

Kidney Function

Monitor Creatinine, Potassium and Glucose

CRAM+2

CRAM + 2 additional analytes TBD

cBMP

CRAM + 2 additional analytes TBD

Metabolytix focus is continuous BMP (cBMP)

OUR PRODUCT ROADMAP: Addressing a Series of Needs


Better Treatment, Improved Patient Experience, and Targeting Lower Cost

Timing	2026		2030	2032
Market Opportunity	Oncology: AKI for chemo patients	Cardiology + Renal: Cardio-Renal Syndrome	TBD: Multiple Opportunities	General Healthcare / Wellness
Product	Cardio-Renal Analyte Monitor (CRAM)		CRAM +2 additional analytes	Full cBMP
Capabilities	Creatinine (Cr) Potassium (K) Glucose (Glu)		CRAM (Cr, K, GLU) Plus 2 of: Carbon Dioxide (CO2) Blood Urea Nitrogen (BUN) Calcium (Ca) Chloride (Cl) Sodium (Na)	Creatinine (Cr) Potassium (K) Glucose (Glu) Carbon Dioxide (CO2) Blood Urea Nitrogen (BUN) Calcium (Ca) Chloride (Cl) Sodium (Na)

Metabolytix Will Focus on High Impact, Limited Applications and Expand Analytes Over Time




OUR PRODUCT ROADMAP: Addressing a Series of Needs

Metabolytix Plans A Sequential and Additive Product Roadmap



Targeting Minimum Viable Product Launch in 2026


MARKET OPPORTUNITIES

	CRAM	CRAM+2	cBMP
 Oncology	✓		
 Cardiology	✓		
 Renal Care	✓		
 Sleep Disorders		✓	
 Weight Loss		✓	
 Gen'l Healthcare			✓
 Wellness			✓
 Fitness			✓

OUR VALUE PROPOSITION


Improving Outcomes, Reducing Costs Across the Patient and Survivor Journey

The Patient Journey



WHERE WE ARE, WHERE WE'RE GOING.

Metabolytix Is Entering the Innovation Phase to Progress Toward First-in-Man Application



WE ARE HERE.

Our research phase is (nearly) complete.

We are readying to move into the Innovation Phase.

The Next Major Milestone: First in Man for our Continuous Cardio-Renal Analyte Monitor (CRAM)

HOW WE GET THERE:

Key Innovation Phase Activities

Key Innovation Stage Milestones Have Been Established



Technology

Validation
Licensing



Market

Select Clinical Partners



Reimbursement

Quantify Value Proposition
Quantify Cost Effectiveness
Reimbursement Strategy



Product

Proof of concept Prototyping
Integration for Manufacturability



Team

Expand Engineering Team

cBMP: The Next Stage of Continuous Metabolic Monitoring

Today's BMP is an obstacle to telemedicine delivery, cBMP enables telemedicine for tomorrow

Improvements in BMP enabled by advancing technologies;
Metabolytix: highly focused on cBMP


Today's BMP works but has not kept pace with dynamic technology changes

Current BMP is an obstacle to telemedicine delivery and more effective treatment of patients

Metabolytix founding team is strong and well positioned in the Phoenix MedTech Ecosystem

cBMP is an attractive market opportunity with long runway.

Now is the time for Metabolytix



Note: individuals of any age who use wired or wireless devices that remotely track or collect well-being or medical data from the user outside a traditional healthcare setting at least once per month, and exchange it via the internet with electronic health records accessed by a medical professional or healthcare provider; includes wearable devices, home health devices, and sensors

Source: Insider Intelligence, Aug 2021

269585

InsiderIntelligence.com

By 2022, 45.1 million US patients will use RPM tools. Insider Intelligence

Metabolytix: Enabling the future of medicine, health, wellness, and wellbeing.

CONTACT

Anthony Bajoras
CEO, Co-Founder



anthony@metabolytix.com
602-821-1500